



# **A Pilot Study Comparing Anterior Femoral Cutaneous Nerve Blocks to Adductor Canal Blocks in Pediatric Ambulatory Knee Surgeries**

FUNDER: Anesthesiology Research Department

PROTOCOL NO.: 2024-0582

VERSION & DATE: Version 1, 8/1/2024

This document contains the confidential information of the Hospital for Special Surgery. It is provided to you and your company's personnel for review. Your acceptance of this document constitutes an agreement that you will not disclose the information contained herein to others without

the prior written consent of the Hospital for Special Surgery. No other use or reproduction is authorized by Hospital for Special Surgery, nor does the Hospital for Special Surgery assume any responsibility for unauthorized use of this protocol.

## TABLE OF CONTENTS

<b>TABLE OF CONTENTS .....</b>	<b>2</b>
<b>PROTOCOL SYNOPSIS .....</b>	<b>4</b>
<b>1.0 INTRODUCTION.....</b>	<b>5</b>
<b>2.0 OBJECTIVE OF CLINICAL STUDY .....</b>	<b>5</b>
<b>3.0 STUDY HYPOTHESES .....</b>	<b>6</b>
<b>4.0 STUDY DESIGN .....</b>	<b>6</b>
4.1 Study Duration.....	6
4.2 Endpoints .....	6
4.2.1 Primary outcome.....	6
4.2.2 Secondary outcome(s).....	6
4.3 Study Sites .....	6
<b>5.0 STUDY POPULATION .....</b>	<b>6</b>
5.1 Number of Subjects.....	6
5.2 Inclusion Criteria.....	6
5.3 Exclusion Criteria .....	7
5.4 Randomization .....	7
<b>6.0 PROCEDURES.....</b>	<b>7</b>
6.1 Surgical Procedure.....	7
6.2 Medical Record Requirements.....	7
6.3 Data Collection .....	7
6.4 Schedule of Assessments.....	9
<b>7.0 STATISTICAL ANALYSIS.....</b>	<b>10</b>
<b>8.0 ADVERSE EVENT ASSESSMENT .....</b>	<b>10</b>
8.1 Adverse Event (AE).....	10
8.2 Serious Adverse Events (SAE) .....	10
8.3 Adverse Event Relationship .....	10
8.4 Adverse Event Recording .....	10
8.5 Adverse Event Reporting .....	10
<b>9.0 INVESTIGATOR RESPONSIBILITIES, RECORD AND REPORTS.....</b>	<b>10</b>
9.1 Subject Consent and Information .....	10

---

9.2	Subject Data Protection .....	11
9.3	Staff Information.....	11
9.4	Protocol Reviews.....	11
<b>10.0</b>	<b>REFERENCES .....</b>	<b>11</b>

## PROTOCOL SYNOPSIS

<b>Protocol Title:</b>	A Pilot Study Comparing Anterior Femoral Cutaneous Nerve Blocks to Adductor Canal Blocks in Pediatric Ambulatory Knee Surgeries
<b>Protocol Number:</b>	2024-0582
<b>Protocol Date:</b>	6/14/2024
<b>Sponsor:</b>	Anesthesiology Research Department
<b>Principal Investigator:</b>	Kathryn DelPizzo
<b>Products:</b>	N/A
<b>Objective:</b>	The goal of this pilot study is to collect information on the effects of the Anterior Femoral Cutaneous Nerve Block (AFCNB) compared to the Adductor Canal Block (ACB) in adolescent patients undergoing ambulatory knee surgery at the Hospital for Special Surgery.
<b>Study Design:</b>	A double-blinded, pilot parallel group-randomized trial (GRT)
<b>Enrollment:</b>	60 subjects
<b>Subject Criteria:</b>	<ol style="list-style-type: none"><li>1. 8-18 years old at the time of surgery</li><li>2. Patients 40kg and above</li><li>3. ACL repair or MPFL reconstruction surgery with participating surgeons</li></ol>
<b>Study Duration:</b>	<ol style="list-style-type: none"><li>1. 3 years (anticipated)</li></ol>
<b>Data Collection:</b>	<ul style="list-style-type: none"><li>Demographics, patient-reported outcomes, pain and satisfaction survey/questionnaires</li></ul>
<b>Outcome Parameters:</b>	<ul style="list-style-type: none"><li>Postoperative function (motor strength in quadriceps)</li><li>Opioid consumption, NRS pain at rest &amp; with ambulation, pain expectation scale, satisfaction with pain management, postoperative sensation, postoperative function</li></ul>
<b>Data Evaluation:</b>	PACU, post operative 6 hrs, 24 hrs, 48 hrs, 7 days, 14 days, 6 weeks, 6 months
<b>Statistical Analysis:</b>	For this pilot study, we are incorporating the “rule of 12” for continuous outcome in our sample size. A sample size of n=15 per treatment group, to account for potential attrition, for a total of 60 patients.

## 1.0 INTRODUCTION

The current focus and trend of pediatric postoperative pain management research involves increased opioid stewardship and regional anesthesia use [1-3]. Previous studies have highlighted the importance of regional anesthesia during knee surgery such as ACL reconstruction, suggesting that perioperative adductor canal block is safe [4] for pediatric patients, and beneficial for reducing pain and minimizing muscle weakness in the immediate postoperative in adult patients [5-10]. Controversy remains on the potential residual effects on functional outcomes with adult patients receiving ACBs, and there is limited data on outcomes in younger patients. A study by Christensen et al suggested that there is prolonged postoperative quadriceps weakness after ACL reconstructions in adults who received an ACB [11]. In a recent retrospective study evaluating quadriceps and hamstring strength in adolescent patients who underwent primary unilateral ACL between July 2008 and January 2018 at a single institution, isokinetic quadriceps deficits were measured at 4-8 months postoperatively in patients who received either a femoral nerve block (n = 36), ACB (n = 31) or no block. The authors found no significant difference in isokinetic quadriceps function among the three groups (@ 5.61 ± 2 months), though they identified a trend towards more negative value in the ACB group suggesting of greater muscle weakness.

There was, however, a significantly lower knee flexion peak torque in the hamstring of patients who received the ACB compared to FNB group. Limitations include the retrospective nature of the study, procedures limited to hamstring autografts, inclusion of patients who did or did not have meniscal repairs, variations in anesthetic technique and doses, as well as in postoperative physical therapy approaches.

Targeting the anterior femoral cutaneous nerve (AFCNB) is a motor sparing technique that provides incisional pain relief but also targets the fascia lata which is integral to the knee and surgically traumatized during knee surgeries. The entire kneecap is blocked when targeting the AFCN in the medial thigh.<sup>13, 14</sup>

No prospective randomized controlled studies have been conducted in pediatric ACL and MPFL reconstruction patients that compare pain intensity levels, opioid consumption and muscle strength in the acute perioperative period and later time points with different peripheral nerve blocks. To our knowledge, this will be the first pediatric study to prospectively collect data from patients receiving AFCNB vs. ACB.

## 2.0 OBJECTIVE OF CLINICAL STUDY

There is scant literature on the efficacy of peripheral nerve blocks or the comparative effectiveness of anesthesia and analgesia techniques in pediatric/adolescent patients undergoing orthopedic procedures, particularly ambulatory knee procedures such as anterior cruciate ligament (ACL) reconstruction. The Pediatric Regional Anesthesia Network, PRAN, to which the study team has contributed information, has focused on safety, rather than efficacy, of regional techniques. The efficacy of these regional techniques in this demographic has not been investigated and therefore represents a vital knowledge gap.

Moreover, there is practice variation at HSS with regard to how patients are blocked for ACL reconstruction surgery. While most surgeons request an adductor canal block (ACB), others do not, citing concerns with potential immediate and persistent functional motor deficits. Given the innervation to the knee and concern with residual functional impairment,

the goal of our pilot study is to collect preliminary information comparing the AFCNB vs ACB, in the hopes of using this data to power a larger randomized controlled trial to rigorously study this clinical question.

### **3.0 STUDY HYPOTHESES**

As this is a pilot study, no formal hypothesis testing will be performed.

### **4.0 STUDY DESIGN**

A double-blinded, pilot parallel group-randomized trial (GRT)

#### **4.1 Study Duration**

Approximately 3 years

#### **4.2 Endpoints**

Primary and secondary outcomes

##### **4.2.1 Primary outcome**

- Postoperative function (motor strength in quadriceps)

##### **4.2.2 Secondary outcome(s)**

- Cumulative opioid consumption
- NRS at rest & with ambulation
- Pain expectation scale
- Satisfaction with Pain Management
- Postoperative sensation
- Postoperative function

#### **4.3 Study Sites**

Hospital for Special Surgery, New York, New York

### **5.0 STUDY POPULATION**

#### **5.1 Number of Subjects**

60

#### **5.2 Inclusion Criteria**

Subjects of either gender will be included if they:

1. 8-18 years old at the time of surgery
2. Patients 40kg and above
3. ACL repair or MPFL reconstruction surgery with participating surgeons
- 4.

### 5.3 Exclusion Criteria

Subjects will be excluded from the study if they:

1. Revision surgery
2. Bilateral surgery
3. General anesthesia
4. Contraindications to any part of the study protocol
5. Relevant pre-existing neurological deficit
6. Chronic pain

### 5.4 Randomization

30 ACL subjects, randomized to either Adductor Canal Block (15) or Anterior Femoral Cutaneous Nerve Block (15).

30 MPFL subjects, randomized to either Adductor Canal Block (15) or Anterior Femoral Cutaneous Nerve Block (15).

## 6.0 PROCEDURES

### 6.1 Surgical Procedure

Anterior Cruciate Ligament (ACL)  
Medial Patellofemoral Ligament (MPFL)

### 6.2 Medical Record Requirements

Basic demographic variables: Name, MRN, DOB, Race, Sex, Ethnicity, Height, Weight, BMI

### 6.3 Data Collection

The following data will be collected:

#### Pre-operative/Baseline

- basic demographic data
- patient weight & height, BMI
- NRS pain at rest & with ambulation

#### Surgical procedure

- date of surgery
- type of surgery

#### Follow-up visits (PACU, POD 1-4, 7, 2 wks, 6 wks, 3 mo, & 6 mo)

- NRS pain at rest & with ambulation
- Opioid consumption
- Patient satisfaction with pain management
- Pain expectation
- Postoperative sensation
- Quadriceps strength (dynamometer)

---

- Range of motion (goniometer)
- PROMIS-10: physical function score

#### 6.4 Schedule of Assessments

Procedures	Before DOS	Pre-op (Holding area)	POD 0	POD 1-2	POD 7	POD 14	2 weeks, 6 weeks, 3 mo, 6 mo, 1 yr
<b>Informed Consent &amp; Eligibility Review</b>	X						
<b>Obtain Assent from minor patient and Consent from parent or guardian</b>		X					
<b>Randomization</b>		X					
<b>NRS Pain Scores (rest &amp; ambulation)</b>		X	X	X*	X	X	
<b>Opioid consumption</b>			X	X*	X	X	
<b>Patient satisfaction w/pain management</b>					X		
<b>Pain expectation</b>			X	X*	X	X	
<b>Measure of sensation</b>						X	X*
<b>Measure of function</b>						X	X*

\*=Patient will be re-evaluated by the investigator as per standard follow-up post-operatively at the following intervals

## **7.0 STATISTICAL ANALYSIS**

For this pilot study, we are incorporating the “rule of 12” for continuous outcome in our sample size.

A sample size of n=15 per treatment group, to account for potential attrition, for a total of 60 patients.

## **8.0 ADVERSE EVENT ASSESSMENT**

All Adverse Events (AEs) will be reported in the final study report. Definitions for Adverse Event (AE) used in this study are listed below and are based on FDA and international guidelines:

### **8.1 Adverse Event (AE)**

Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product which does not necessarily have to have a causal relationship with this treatment. An adverse event (AE) can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product.

### **8.2 Serious Adverse Events (SAE)**

The event is serious and should be reported to FDA when the patient outcome is: Death, Life-threatening, Hospitalization (initial or prolonged), Disability or Permanent Damage, Congenital Anomaly/Birth Defect, Required Intervention to Prevent Permanent Impairment or Damage (Devices), Other Serious (Important Medical Events).

### **8.3 Adverse Event Relationship**

Relationship to study: definitely, probably, possibly, not related.

### **8.4 Adverse Event Recording**

All adverse events will be recorded in the adverse event log by the research coordinator.

### **8.5 Adverse Event Reporting**

All adverse event reports will be made to the institutional review board as they come up/occur.

## **9.0 INVESTIGATOR RESPONSIBILITIES, RECORD AND REPORTS**

### **9.1 Subject Consent and Information**

Research assistants will screen the co-investigating surgeons' patients undergoing ACL and MPFL surgeries. Screening will involve reviewing the patient's EPIC chart to ensure

that they meet the inclusion criteria and are not excluded due to any of the exclusion criteria listed. Patients who meet the inclusion criteria will be identified as potential study participants. After the investigating anesthesiologists have confirmed the eligibility of all potential participants, one of the investigating anesthesiologists will approach the potential patients in the pre-operative holding area, explain the rationale for the study, and ask if the patient is interested in participating.

## 9.2 Subject Data Protection

Subject privacy and confidentiality will be maintained through the storage of study data in a password-protected computer database maintained by the Research Director and accessible only to the principal investigator, in addition to other IRB-approved study personnel. Each subject will be assigned a unique study number for identification in the study database. This unique study number will not be derived from or related to information about the individual. The key linking this unique study number to patient identifiers (i.e., name, medical record number, date of birth, registry number) will be maintained in a different password-protected database maintained by Research Director, to which only the primary investigator will have access.

## 9.3 Staff Information

Primary Investigator: Kathryn DelPizzo, MD

Research Coordinator: Pa Thor, PhD, 646-797-8535

## 9.4 Protocol Reviews

Study protocol reviewed and approved by:

- Anesthesiology CRP
- Hospital for Special Surgery Institutional Review Board

## 10.0 REFERENCES

1. Liu SS, Strodtbeck WM, Richman JM, Wu CL. A comparison of regional versus general anesthesia for ambulatory anesthesia: a meta-analysis of randomized controlled trials. *Anesth Analg.* 2005;101:1634–1642.
2. Wang C, Liu LD, Bai X. Bibliometric and Visual Analysis of the Current Status and Trends of Postoperative Pain in Children from 1950-2021. *J Pain Res.* 2022;15:3209-3222. Published 2022 Oct 14.
3. Micalizzi RA, Williams LA, Pignataro S, Sethna NF, Zurakowski D. Review of outcomes in pediatric patients undergoing anterior cruciate ligament repairs with regional nerve blocks. *J Pediatr Nurs.* 2014 Nov-Dec;29(6):670-8. Epub 2014 Jul 13. PMID: 25089833.
4. Walker BJ, Long JB, Sathyamoorthy M, et al. Complications in Pediatric Regional Anesthesia: An Analysis of More than 100,000 Blocks from the Pediatric Regional Anesthesia Network. *Anesthesiology.* 2018;129(4):721-732.
5. Yee EJ, Gapinski ZA, Ziembka-Davis M, Nielson M, Meneghini RM. Quadriceps Weakness After Single-Shot Adductor Canal Block: A Multivariate Analysis of 1,083 Primary Total Knee Arthroplasties. *J Bone Joint Surg Am.* 2021;103(1):30-36.
6. Zhao XQ, Jiang N, Yuan FF, Wang L, Yu B. The comparison of adductor canal block with femoral nerve block following total knee arthroplasty: a systematic review with meta-analysis. *J Anesth.* 2016;30(5):745-754.
7. Kuang MJ, Ma JX, Fu L, He WW, Zhao J, Ma XL. Is adductor canal block better than femoral nerve block in primary total knee arthroplasty? A GRADE analysis of the evidence through a

systematic review and meta-analysis. *J Arthroplasty*. 2017 Oct;32(10):3238-3248.e3. Epub 2017 May 17.

8. Jiang X, Wang QQ, Wu CA, Tian W. Analgesic efficacy of adductor canal block in total knee arthroplasty: a meta-analysis and systematic review. *Orthop Surg*. 2016 Aug;8(3):294-300.
9. Abdallah FW, Brull R, Joshi GP; Society for Ambulatory Anesthesia (SAMBA). Pain Management for Ambulatory Arthroscopic Anterior Cruciate Ligament Reconstruction: Evidence-Based Recommendations From the Society for Ambulatory Anesthesia. *Anesth Analg*. 2019;128(4):631-640.
10. Abdallah FW, Whelan DB, Chan VW, et al. Adductor Canal Block Provides Noninferior Analgesia and Superior Quadriceps Strength Compared with Femoral Nerve Block in Anterior Cruciate Ligament Reconstruction. *Anesthesiology*. 2016;124(5):1053-1064.
11. Christensen JE, Taylor NE, Hetzel SJ, Shepler JA, Scerpella TA. Isokinetic Strength Deficit 6 Months After Adductor Canal Blockade for Anterior Cruciate Ligament Reconstruction. *Orthop J Sports Med*. 2017 Nov 8;5(11):2325967117736249. PMID: 29152521; PMCID: PMC5680944.
12. Frazer AR, Chaussé ME, Held M, St-Pierre C, Tsai CY, Preuss R, Descoteaux N, Chan M, Martineau PA, Veilleux LN. Quadriceps and Hamstring Strength in Adolescents 6 Months After ACL Reconstruction With Femoral Nerve Block, Adductor Canal Block, or No Nerve Block. *Orthop J Sports Med*. 2021 Jul 22;9(7):23259671211017516. doi: 10.1177/23259671211017516. PMID: 34368383; PMCID: PMC8312176.
13. Anterior Femoral Cutaneous Nerve Block (Dr. Jeff Gadsden), Accessed from: <https://www.youtube.com/watch?v=zzj08axeE94>
14. Anterior Femoral Cutaneous Nerve Block (Dr. Amit Pawa); Accessed from: <https://www.youtube.com/watch?v=bAxMvcTf0kU>